Ionis Pharmaceuticals (IONS) EVP Schneider Buys $1.6M of Stock

Eugene Schneider, the Executive Vice President and Chief Clinical Development Officer at Ionis Pharmaceuticals, Inc. (NasdaqGS: IONS), made a notable purchase of company stock. On June 26, 2026, Schneider acquired 26,000 shares at an average price of $60.89, totaling approximately $1.58 million. This transaction was not part of a pre-planned trading program.

Other Institutional Activity in Ionis Pharmaceuticals

Several institutional investors have recently adjusted their holdings in Ionis Pharmaceuticals. FMR LLC increased its stake by 484,536 shares, bringing its total to 24,556,637 shares valued at about $1.84 billion, marking a 2% increase. CAPITAL WORLD INVESTORS added 3,225,070 shares, a significant 18% increase, resulting in 21,186,369 shares worth around $1.59 billion. BLACKROCK, INC. trimmed its position slightly by 205,387 shares, ending with 10,442,476 shares valued at $784.1 million, a 1.9% decrease. Meanwhile, VANGUARD PORTFOLIO MANAGEMENT LLC and VANGUARD CAPITAL MANAGEMENT LLC both opened new positions, with 7,808,902 and 7,118,330 shares, respectively.

Ionis Pharmaceuticals, Inc. Stock Up 81.6%

Shares of Ionis Pharmaceuticals traded near $80.69 on Wednesday. The company has a market capitalization of approximately $13.42 billion. Despite not being profitable, Ionis has a forward P/E ratio of -133.39, indicating expectations for future earnings improvements. The stock's beta is 0.37, suggesting lower volatility compared to the market. Over the past year, Ionis shares have ranged from $39.37 to $86.74, with a 50-day moving average of $75.05 and a 200-day moving average of $75.41. The company's financial health is supported by a current ratio of 4.10 and a quick ratio of 2.86, although it carries a high debt-to-equity ratio of 531.05.

Recent Earnings

Ionis Pharmaceuticals reported revenue of $1.06 billion, growing by 0.87% year-over-year. However, the company posted a net margin of -30.9% and a return on equity of -67.6%, reflecting ongoing challenges in achieving profitability. The next earnings report is scheduled for August 5, 2026.

Insider Buying and Selling at Ionis Pharmaceuticals, Inc.

In addition to Eugene Schneider's purchase, Joseph Baroldi, EVP and Chief Business Officer, also made transactions on June 26, 2026. Baroldi sold 5,635 shares at $80.16 as part of a planned sale and bought the same number of shares at $49.19 in an unplanned transaction. Patrick O'Neil, EVP CLO & General Counsel, similarly engaged in planned sales, selling 3,069 shares at $80.00.

Analysts Set New Price Targets

On June 25, 2026, Goldman Sachs maintained a 'hold' rating on Ionis with a price target of $75. Leerink Partners and HC Wainwright & Co. both reaffirmed their 'buy' ratings, setting price targets at $129 and $130, respectively. The consensus among 23 analysts is a 'buy' recommendation, with an average price target of $105.91.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc., based in Carlsbad, California, is a biotechnology company specializing in RNA-targeted medicines. It offers treatments for various conditions, including spinal muscular atrophy and hereditary transthyretin-mediated amyloidosis. The company is also advancing a robust pipeline of therapies for neurological and cardiovascular diseases, in collaboration with partners like Biogen and AstraZeneca. Dr. Brett P. Monia, Ph.D., is the CEO, overseeing a team of approximately 1,402 employees.

Bottom Line

Eugene Schneider's recent purchase highlights insider confidence in Ionis Pharmaceuticals. While the company faces challenges with profitability, its strategic partnerships and strong pipeline continue to draw interest. Investors should note that insider transactions are reported after they occur, and institutional activity can influence stock performance.